New indication concerns the
treatment of locally advanced or metastatic NSCLC of squamous histology
progressing on or after platinum-based chemotherapy
On 25 February 2016, the European Medicines
Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted
a positive opinion recommending a change to the terms of the marketing
authorisation for the medicinal product afatinib (Giotrif).
Read more here.
No comments:
Post a Comment